Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
NBIX News
Advertisement Neurocrine Biosciences ( ) First Quarter 2025 Results Key Financial Results Revenue: US$572.6m (up 11% from 1Q 2024). Net income: US$7.90m (do...
It's been a pretty great week for Neurocrine Biosciences, Inc. ( ) shareholders, with its shares surging 11% to US$119 in the week since its latest quarterly re...
Leerink Partners analyst Marc Goodman reiterated a Buy rating on Neurocrine (NBIX – Research Report) on May 5 and set a price target of $160.00. Marc Goodman h...
Analyst ratings
85%
of 27 ratingsMore NBIX News
Neurocrine Biosciences Inc. NBIX stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings. The company on...
BMO Capital raised the firm’s price target on Neurocrine (NBIX) to $115 from $96 but keeps a Market Perform rating on the shares after its Q1 results. The compa...
BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $115.00. Evan Seigerman’...
William Blair analyst Myles Minter has maintained their bullish stance on NBIX stock, giving a Buy rating yesterday. Myles Minter has given his Buy rating due...